PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
November 6, 1976BMJOpen Access

Streptokinase in acute myocardial infarction: a controlled multicentre study in the United Kingdom.

View Full Paper
Ask AI
Bookmark
Share

Why the study?

Does intravenous streptokinase reduce mortality in patients with acute myocardial infarction?

Population

595 patients with acute myocardial infarction

Comparison

Intravenous infusion of 2,500,000 IU of… vs Control group

Design

RCT

Follow-up

6 months

Authors

CAC. P. AberNBN. M. BassCBC. L. Berry

Discussion

Loading...

Member takes

Overview

Streptokinase shows no mortality benefit in acute MI; challenges assumptions of thrombolytic efficacy and directs research to timing and subgroups.

Structured PICO

Does intravenous streptokinase reduce mortality in patients with acute myocardial infarction?

P
Population
595 patients with acute myocardial infarction
I
Intervention
Intravenous infusion of 2,500,000 IU of streptokinase over 24 hours
C
Comparator
Control group (neither group received anticoagulants unless indicated by thromboembolic complications)
O
Outcome
Mortality (inpatient, six-week, and six-month follow-up)hard clinical

An infusion of streptokinase within 24 hours of the onset of acute myocardial infarction does not significantly affect mortality or the course of the illness up to six months.

Cite This Study

Aber et al. (1976) studied this question.

synapsesocial.com/papers/6a20a12e5049d8f68e91cf57https://doi.org/10.1136/bmj.2.6044.1100
View Full Paper
Ask AI
Bookmark
Share